Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Por Michail Ignatiadis, Dimitrios Zardavas, Marc Lemort, Celine Wilke, Marie-Catherine Vanderbeeken, Veronique D'Hondt, Evandro De Azambuja, Andrea Gombos, Fabienne Lebrun, Lissandra Dal Lago, Fanny Bustin, Marion Maetens, Lieveke Ameye, Isabelle Veys, Stefan Michiels, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Jean-Marie Nogaret, Martine Piccart, Ahmad Awada
Publicado em 2016-01-01